IVOS Medical, Inc., a medical device company specializing in airway management, has received a Small Business Innovation Research (SBIR) Phase II grant of approximately $1.9 million from the National Institutes of Health (NIH). The funding, awarded by the National Heart, Lung, And Blood Institute (NHLBI), will support the continued development and clinical validation of the IVOS BOSS G4™ video laryngoscope.
The IVOS BOSS G4™ is designed as an economical, single-use video laryngoscope sheath that incorporates novel features to maintain clear vision during intubation, particularly in emergency and soiled intubations. The device aims to increase first-pass success rates, addressing a critical need in emergency medicine and anesthesiology.
Addressing Challenges in Airway Management
Effective airway management is crucial in various clinical settings, including emergency rooms and operating rooms. Difficult or failed intubations can lead to severe complications, including hypoxia and death. The IVOS BOSS G4™ seeks to mitigate these risks by providing a clear view of the airway, even in challenging circumstances.
"I am grateful for the tremendous support from the NHLBI... for backing our research and advancing this lifesaving technology," said Gabriel Punsalan, CRNA, MS, CEO and Co-Founder of IVOS Medical. He also acknowledged the support of the University of California Medical Center’s Departments of Anesthesiology and Emergency Medicine clinicians in testing the BOSS G4 during feasibility studies.
Clinical Validation and Future Steps
The Phase II SBIR award will enable IVOS Medical to complete product development and achieve clinical validation of the BOSS G4. This follows a Phase I grant of $247,334 awarded in Fiscal Year 2022, which demonstrated the feasibility of the technology. The company's focus is now on bringing the device to market and improving patient outcomes.
"This SBIR Phase II award underscores the importance of IVOS’s value proposition, product, and the team’s ability to successfully execute on its Phase I milestones," stated Francis Duhay, MD, MBA, IVOS’s Business Advisor and Partner. "Our current aims focus on completing product development and achieving clinical validation, bringing us one giant step closer to the patients who would benefit the most."
